Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Retinoic acid receptor α as a novel contributor to adrenal cortex structure and function through interactions with Wnt and Vegfa signalling.

El Zein RM, Soria AH, Golib Dzib JF, Rickard AJ, Fernandes-Rosa FL, Samson-Couterie B, Giscos-Douriez I, Rocha A, Poglitsch M, Gomez-Sanchez CE, Amar L, Ghyselinck NB, Benecke A, Zennaro MC, Boulkroun S.

Sci Rep. 2019 Oct 11;9(1):14677. doi: 10.1038/s41598-019-50988-2.

2.

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure.

Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC Jr, Llorens-Cortes C, Ehlers MR, Sturrock ED.

Pharmacol Rev. 2019 Oct;71(4):539-570. doi: 10.1124/pr.118.017129. Review.

PMID:
31537750
3.

Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation.

Kovarik JJ, Kaltenecker CC, Kopecky C, Domenig O, Antlanger M, Werzowa J, Eskandary F, Kain R, Poglitsch M, Schmaldienst S, Böhmig GA, Säemann MD.

Sci Rep. 2019 Jul 5;9(1):9762. doi: 10.1038/s41598-019-46114-x.

4.

Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction.

Binder C, Poglitsch M, Agibetov A, Duca F, Zotter-Tufaro C, Nitsche C, Aschauer S, Kammerlander AA, Oeztuerk B, Hengstenberg C, Mascherbauer J, Bonderman D.

Hypertension. 2019 Aug;74(2):285-294. doi: 10.1161/HYPERTENSIONAHA.119.12786. Epub 2019 Jun 24.

PMID:
31230551
5.

Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.

Wang W, Shen M, Fischer C, Basu R, Hazra S, Couvineau P, Paul M, Wang F, Toth S, Mix DS, Poglitsch M, Gerard NP, Bouvier M, Vederas JC, Penninger JM, Kassiri Z, Oudit GY.

Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):13006-13015. doi: 10.1073/pnas.1900152116. Epub 2019 Jun 12.

6.

Aldosterone Stimulates Its Biosynthesis Via A Novel GPER Mediated Mechanism.

Caroccia B, Seccia TM, Piazza M, Prisco S, Zanin S, Iacobone M, Lenzini L, Pallafacchina G, Domening O, Poglitsch M, Rizzuto R, Rossi GP.

J Clin Endocrinol Metab. 2019 May 24. pii: jc.2019-00043. doi: 10.1210/jc.2019-00043. [Epub ahead of print]

PMID:
31125081
7.

Identifying a disease-specific renin-angiotensin-aldosterone system fingerprint in patients with primary adrenal insufficiency.

Wolf P, Mayr J, Beiglböck H, Fellinger P, Winhofer Y, Poglitsch M, Gessl A, Kautzky-Willer A, Luger A, Krebs M.

Eur J Endocrinol. 2019 Jul 1;181(1):39-44. doi: 10.1530/EJE-19-0086.

PMID:
31075757
8.

Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen.

Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, de Vries R, Poglitsch M, Zlatev I, Kim JB, Hoorn EJ, Foster D, Danser AHJ.

Hypertension. 2019 Jun;73(6):1249-1257. doi: 10.1161/HYPERTENSIONAHA.119.12703.

PMID:
31030610
9.

Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus.

Kopecky C, Lytvyn Y, Domenig O, Antlanger M, Kovarik JJ, Kaltenecker CC, Poglitsch M, Perkins BA, Rye KA, Cherney DZI, Säemann MD.

Diabetologia. 2019 Jun;62(6):1090-1093. doi: 10.1007/s00125-019-4871-8. Epub 2019 Apr 11. No abstract available.

PMID:
30976852
10.

Losartan prevents the elevation of blood pressure in adipose-PRR deficient female mice while elevated circulating sPRR activates the renin-angiotensin system.

Gatineau E, Cohn DM, Poglitsch M, Loria AS, Gong M, Yiannikouris F.

Am J Physiol Heart Circ Physiol. 2019 Mar 1;316(3):H506-H515. doi: 10.1152/ajpheart.00473.2018. Epub 2018 Dec 14.

PMID:
30550352
11.

Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension.

Simko F, Baka T, Poglitsch M, Repova K, Aziriova S, Krajcirovicova K, Zorad S, Adamcova M, Paulis L.

Int J Mol Sci. 2018 Oct 3;19(10). pii: E3017. doi: 10.3390/ijms19103017.

12.

Studying Huntington's Disease in Yeast: From Mechanisms to Pharmacological Approaches.

Hofer S, Kainz K, Zimmermann A, Bauer MA, Pendl T, Poglitsch M, Madeo F, Carmona-Gutierrez D.

Front Mol Neurosci. 2018 Sep 4;11:318. doi: 10.3389/fnmol.2018.00318. eCollection 2018. Review.

13.

Aldosterone LC-MS/MS Assay-Specific Threshold Values in Screening and Confirmatory Testing for Primary Aldosteronism.

Guo Z, Poglitsch M, McWhinney BC, Ungerer JPJ, Ahmed AH, Gordon RD, Wolley M, Stowasser M.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):3965-3973. doi: 10.1210/jc.2018-01041.

PMID:
30137438
14.

Protective effects of the angiotensin II AT2 receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach.

Bennion DM, Jones CH, Dang AN, Isenberg J, Graham JT, Lindblad L, Domenig O, Waters MF, Poglitsch M, Sumners C, Steckelings UM.

Clin Sci (Lond). 2018 Mar 15;132(5):581-593. doi: 10.1042/CS20180100. Print 2018 Mar 15.

PMID:
29500223
15.

Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension.

Simko F, Baka T, Krajcirovicova K, Repova K, Aziriova S, Zorad S, Poglitsch M, Adamcova M, Reiter RJ, Paulis L.

Molecules. 2018 Jan 29;23(2). pii: E265. doi: 10.3390/molecules23020265.

16.

Mitochondrial energy metabolism is required for lifespan extension by the spastic paraplegia-associated protein spartin.

Ring J, Rockenfeller P, Abraham C, Tadic J, Poglitsch M, Schimmel K, Westermayer J, Schauer S, Achleitner B, Schimpel C, Moitzi B, Rechberger GN, Sigrist SJ, Carmona-Gutierrez D, Kroemer G, Büttner S, Eisenberg T, Madeo F.

Microb Cell. 2017 Nov 30;4(12):411-422. doi: 10.15698/mic2017.12.603.

17.

Low- and High-renin Heart Failure Phenotypes with Clinical Implications.

Pavo N, Goliasch G, Wurm R, Novak J, Strunk G, Gyöngyösi M, Poglitsch M, Säemann MD, Hülsmann M.

Clin Chem. 2018 Mar;64(3):597-608. doi: 10.1373/clinchem.2017.278705. Epub 2017 Nov 14.

18.

Can Screening and Confirmatory Testing in the Management of Patients with Primary Aldosteronism be Improved?

Stowasser M, Ahmed A, Guo Z, Wolley M, Ungerer J, McWhinney B, Poglitsch M, Gordon R.

Horm Metab Res. 2017 Dec;49(12):915-921. doi: 10.1055/s-0043-121468. Epub 2017 Nov 13. Review.

PMID:
29132172
19.

Urotensin II Exerts Pressor Effects By Stimulating Renin And Aldosterone Synthase Gene Expression.

Caroccia B, Menegolo M, Seccia TM, Petrelli L, Antonello M, Limena A, Porzionato A, De Caro R, Poglitsch M, Rossi GP.

Sci Rep. 2017 Oct 24;7(1):13876. doi: 10.1038/s41598-017-12613-y.

20.

Reply: RAS Fingerprint.

Poglitsch M, Basu R, Oudit GY.

J Am Coll Cardiol. 2017 Jun 20;69(24):3011-3013. doi: 10.1016/j.jacc.2017.03.603. No abstract available.

21.

Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.

Xu J, Sriramula S, Xia H, Moreno-Walton L, Culicchia F, Domenig O, Poglitsch M, Lazartigues E.

Circ Res. 2017 Jun 23;121(1):43-55. doi: 10.1161/CIRCRESAHA.116.310509. Epub 2017 May 16.

22.

Molecular remodeling of the renin-angiotensin system after kidney transplantation.

Antlanger M, Domenig O, Kovarik JJ, Kaltenecker CC, Kopecky C, Poglitsch M, Säemann MD.

J Renin Angiotensin Aldosterone Syst. 2017 Apr-Jun;18(2):1470320317705232. doi: 10.1177/1470320317705232.

23.

Brain Renin-Angiotensin System: Does It Exist?

van Thiel BS, Góes Martini A, Te Riet L, Severs D, Uijl E, Garrelds IM, Leijten FPJ, van der Pluijm I, Essers J, Qadri F, Alenina N, Bader M, Paulis L, Rajkovicova R, Domenig O, Poglitsch M, Danser AHJ.

Hypertension. 2017 Jun;69(6):1136-1144. doi: 10.1161/HYPERTENSIONAHA.116.08922. Epub 2017 Apr 10.

PMID:
28396529
24.

Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease.

Antlanger M, Bernhofer S, Kovarik JJ, Kopecky C, Kaltenecker CC, Domenig O, Poglitsch M, Säemann MD.

Ann Med. 2017 Sep;49(6):525-533. doi: 10.1080/07853890.2017.1313447. Epub 2017 Apr 17.

PMID:
28358246
25.

Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure.

Basu R, Poglitsch M, Yogasundaram H, Thomas J, Rowe BH, Oudit GY.

J Am Coll Cardiol. 2017 Feb 21;69(7):805-819. doi: 10.1016/j.jacc.2016.11.064.

26.

Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction.

Pavo N, Wurm R, Goliasch G, Novak JF, Strunk G, Gyöngyösi M, Poglitsch M, Säemann MD, Hülsmann M.

J Am Coll Cardiol. 2016 Dec 27;68(25):2912-2914. doi: 10.1016/j.jacc.2016.10.017. No abstract available.

27.

Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.

Kovarik JJ, Kopecky C, Antlanger M, Domenig O, Kaltenecker CC, Werzowa J, Hecking M, Mahr S, Grömmer M, Wallner C, Aumayr K, Kain R, Zuckermann A, Poglitsch M, Säemann MD.

J Heart Lung Transplant. 2017 Mar;36(3):355-365. doi: 10.1016/j.healun.2016.08.022. Epub 2016 Sep 13.

PMID:
27773450
28.

Quantification of systemic renin-angiotensin system peptides of hypertensive black and white African men established from the RAS-Fingerprint®.

van Rooyen JM, Poglitsch M, Huisman HW, Mels C, Kruger R, Malan L, Botha S, Lammertyn L, Gafane L, Schutte AE.

J Renin Angiotensin Aldosterone Syst. 2016 Oct 12;17(4). pii: 1470320316669880. Print 2016 Oct.

29.

Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney.

Domenig O, Manzel A, Grobe N, Königshausen E, Kaltenecker CC, Kovarik JJ, Stegbauer J, Gurley SB, van Oyen D, Antlanger M, Bader M, Motta-Santos D, Santos RA, Elased KM, Säemann MD, Linker RA, Poglitsch M.

Sci Rep. 2016 Sep 21;6:33678. doi: 10.1038/srep33678.

30.

Effects of ACE2 deficiency on physical performance and physiological adaptations of cardiac and skeletal muscle to exercise.

Motta-Santos D, Dos Santos RA, Oliveira M, Qadri F, Poglitsch M, Mosienko V, Kappes Becker L, Campagnole-Santos MJ, M Penninger J, Alenina N, Bader M.

Hypertens Res. 2016 Jul;39(7):506-12. doi: 10.1038/hr.2016.28. Epub 2016 Apr 7.

PMID:
27053009
31.

Hypertensive retinopathy in a transgenic angiotensin-based model.

Reichhart N, Haase N, Crespo-Garcia S, Skosyrski S, Herrspiegel C, Kociok N, Fuchshofer R, Dillinger A, Poglitsch M, Müller DN, Joussen AM, Luft FC, Dechend R, Strauß O.

Clin Sci (Lond). 2016 Jul 1;130(13):1075-88. doi: 10.1042/CS20160092. Epub 2016 Mar 29.

PMID:
27026533
32.

Letter to the editor: Angiotensin quantification by mass spectrometry.

Poglitsch M, Sturrock ED, Danser AH.

Am J Physiol Heart Circ Physiol. 2016 Feb 1;310(3):H452-3. doi: 10.1152/ajpheart.00933.2015. No abstract available.

33.

Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.

Roksnoer LC, van Veghel R, de Vries R, Garrelds IM, Bhaggoe UM, Friesema EC, Leijten FP, Poglitsch M, Domenig O, Clahsen-van Groningen MC, Hoorn EJ, Jan Danser AH, Batenburg WW.

Kidney Int. 2015 Jul;88(1):109-20. doi: 10.1038/ki.2015.107. Epub 2015 Apr 1.

34.

Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.

Sharp S, Poglitsch M, Zilla P, Davies NH, Sturrock ED.

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1149-58. doi: 10.1177/1470320314568438. Epub 2015 Mar 9.

PMID:
25757657
35.

Vitamin D depletion aggravates hypertension and target-organ damage.

Andersen LB, Przybyl L, Haase N, von Versen-Höynck F, Qadri F, Jørgensen JS, Sorensen GL, Fruekilde P, Poglitsch M, Szijarto I, Gollasch M, Peters J, Muller DN, Christesen HT, Dechend R.

J Am Heart Assoc. 2015 Jan 28;4(2). pii: e001417. doi: 10.1161/JAHA.114.001417.

36.

Lysis gradient centrifugation: a flexible method for the isolation of nuclei from primary cells.

Katholnig K, Poglitsch M, Hengstschläger M, Weichhart T.

Methods Mol Biol. 2015;1228:15-23. doi: 10.1007/978-1-4939-1680-1_2.

PMID:
25311118
37.

Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease.

Manzel A, Domenig O, Ambrosius B, Kovacs A, Stegbauer J, Poglitsch M, Mueller DN, Gold R, Linker RA.

J Neuroimmune Pharmacol. 2014 Sep;9(4):533-43. doi: 10.1007/s11481-014-9548-y. Epub 2014 May 23.

PMID:
24854706
38.

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects.

Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krähenbühl S.

Clin Pharmacokinet. 2013 Sep;52(9):783-92. doi: 10.1007/s40262-013-0072-7.

PMID:
23681967
39.

Weight loss and weight regain-5-year follow-up for circular- vs. linear-stapled gastrojejunostomy in laparoscopic Roux-en-Y gastric bypass.

Langer FB, Prager G, Poglitsch M, Kefurt R, Shakeri-Leidenmühler S, Ludvik B, Schindler K, Bohdjalian A.

Obes Surg. 2013 Jun;23(6):776-81. doi: 10.1007/s11695-013-0892-4.

PMID:
23483356
40.

[3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase.

Nikolaou A, Van den Eynde I, Tourwé D, Vauquelin G, Tóth G, Mallareddy JR, Poglitsch M, Van Ginderachter JA, Vanderheyden PM.

Eur J Pharmacol. 2013 Feb 28;702(1-3):93-102. doi: 10.1016/j.ejphar.2013.01.026. Epub 2013 Jan 31.

PMID:
23376157
41.

Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Ye M, Wysocki J, Gonzalez-Pacheco FR, Salem M, Evora K, Garcia-Halpin L, Poglitsch M, Schuster M, Batlle D.

Hypertension. 2012 Sep;60(3):730-40. doi: 10.1161/HYPERTENSIONAHA.112.198622. Epub 2012 Jul 9.

42.

Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System.

Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M.

Int J Hypertens. 2012;2012:428950. doi: 10.1155/2012/428950. Epub 2012 Feb 28.

43.

CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.

Poglitsch M, Weichhart T, Hecking M, Werzowa J, Katholnig K, Antlanger M, Krmpotic A, Jonjic S, Hörl WH, Zlabinger GJ, Puchhammer E, Säemann MD.

Am J Transplant. 2012 Jun;12(6):1458-68. doi: 10.1111/j.1600-6143.2012.04002.x. Epub 2012 Mar 5.

44.

Rapid isolation of nuclei from living immune cells by a single centrifugation through a multifunctional lysis gradient.

Poglitsch M, Katholnig K, Säemann MD, Weichhart T.

J Immunol Methods. 2011 Oct 28;373(1-2):167-73. doi: 10.1016/j.jim.2011.08.012. Epub 2011 Aug 24.

PMID:
21889513
45.

Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells.

Weichhart T, Haidinger M, Katholnig K, Kopecky C, Poglitsch M, Lassnig C, Rosner M, Zlabinger GJ, Hengstschläger M, Müller M, Hörl WH, Säemann MD.

Blood. 2011 Apr 21;117(16):4273-83. doi: 10.1182/blood-2010-09-310888. Epub 2011 Mar 2.

PMID:
21368289
46.

Mesh fixation in laparoscopic incisional hernia repair: glue fixation provides attachment strength similar to absorbable tacks but differs substantially in different meshes.

Rieder E, Stoiber M, Scheikl V, Poglitsch M, Dal Borgo A, Prager G, Schima H.

J Am Coll Surg. 2011 Jan;212(1):80-6. doi: 10.1016/j.jamcollsurg.2010.08.015. Epub 2010 Oct 29.

PMID:
21036072
47.

A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.

Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Hörl WH, Säemann MD, Weichhart T.

J Immunol. 2010 Oct 1;185(7):3919-31. doi: 10.4049/jimmunol.1000296. Epub 2010 Aug 30.

48.

The versatility of HDL: a crucial anti-inflammatory regulator.

Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T.

Eur J Clin Invest. 2010 Dec;40(12):1131-43. doi: 10.1111/j.1365-2362.2010.02361.x. Review.

PMID:
20695882
49.

Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.

Haidinger M, Hecking M, Weichhart T, Poglitsch M, Enkner W, Vonbank K, Prayer D, Geusau A, Oberbauer R, Zlabinger GJ, Soleiman A, Hörl WH, Säemann MD.

Transpl Int. 2010 Aug;23(8):777-85. doi: 10.1111/j.1432-2277.2009.01041.x. Epub 2010 Jan 11.

50.

The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, Müller M, Säemann MD.

Immunity. 2008 Oct 17;29(4):565-77. doi: 10.1016/j.immuni.2008.08.012. Epub 2008 Oct 9.

Supplemental Content

Loading ...
Support Center